Startup profile · funding coverage
Precision BioSciences funding, valuation and investors
Gene editing company using ARCUS genome editing for therapeutics and related applications.
Keep track of Precision BioSciences
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Not publicly disclosed
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
public
public · Durham, NC
Overview
Precision BioSciences develops ARCUS gene-editing technology for therapeutic and other genomic applications. Based in Durham, North Carolina; publicly traded as DTIL.
Why Precision BioSciences is interesting
Durham public gene-editing biotech (NASDAQ: DTIL) — Research Triangle life-science flagship founders actually mean when they search RTP.
Product & use cases
ARCUS nuclease platform for gene editing therapeutics and partnerships.
- In vivo gene editing therapeutics
- Partnered genomic applications
Key facts
- Durham HQ — NASDAQ:DTIL
- ARCUS gene editing platform
- Founded 2006
Competitive landscape
Edge: Proprietary ARCUS editor differentiated from CRISPR-centric platforms.
-
CRISPR Therapeutics / Intellia / Beam direct
Gene editing therapeutic companies.
Industries
Market / IPO context
Ticker: DTIL (NASDAQ)
IPO status: public
Editorial / static context — not a live quote.
FAQs about Precision BioSciences
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.